A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome.
Nataly Stylianou, Melanie L Lehman, Chenwei Wang, Atefeh Taherian Fard, Anja Rockstroh, Ladan Fazli, Lidija Jovanovic, Micheal Ward, Martin C Sadowski, Abhishek S Kashyap, Ralph Buttyan, Martin E Gleave, Thomas F Westbrook, Elizabeth D Williams, Jennifer H Gunter, Colleen C Nelson, Brett G Hollier
Oncogene | Published : 2019
The propensity of cancer cells to transition between epithelial and mesenchymal phenotypic states via the epithelial-mesenchymal transition (EMT) program can regulate metastatic processes, cancer progression, and treatment resistance. Transcriptional investigations using reversible models of EMT, revealed the mesenchymal-to-epithelial reverting transition (MErT) to be enriched in clinical samples of metastatic castrate resistant prostate cancer (mCRPC). From this enrichment, a metastasis-derived gene signature was identified that predicted more rapid cancer relapse and reduced survival across multiple human carcinoma types. Additionally, the transcriptional profile of MErT is not a simple mi..View full abstract